TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01669941

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IPTp-SP
Description: 3 tablets of sulfadoxine (500 mg) and pyrimethamine (25 mg) given at each ANC visit

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPTp-DP
Description: At each ANC visit: treatment with Dihydroartemisinin-piperaquine for three days, with the daily number of tablets depending on the weight of the woman; two tablets for women weighing 24- 35.9kg, three tablets for women weighing 36 to 74.9 kg, and four tablets for women weighing 75kg or more. The first dose will be observed; the woman will be given the additional 2 doses to take at home and there may be a home visit to confirm that the tablets were taken.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISTp-DP
Description: At each ANC visit, women will be screened for malaria using a combined HRP-2/ pLDH (P. falciparum/ pan-malaria) rapid diagnostic test, and if positive, treated with dihydroartemisinin-piperaquine. Each tablet will contain 40 mg dihydroartemisinin and 320 mg piperaquine. Treatment will be given for three days, with the daily number of tablets depending on the weight of the woman; two tablets for women weighing 24- 35.9kg, three tablets for women weighing 36 to 74.9 kg, and four tablets for women weighing 75kg or more. The first dose will be observed; the woman will be given the additional 2 doses to take at home
Study: NCT01308723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5323441
Description: escalating doses iv

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5323441
Description: iv every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib
Description: 400 mg orally twice daily to once every other day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib
Description: 400 mg orally twice daily to once every other day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sorafenib
Description: 400 mg orally twice daily to once every other day
Study: NCT01254513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel every 3 weeks + Prednisone
Description: * Docetaxel IV 60 mg/m²/d then IV 70 mg/m²/d for subsequent cycles every 3 weeks~* Prednisone 10 mg/day continuously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel weekly+ Prednisone
Description: * Docetaxel weekly 35 mg/m²/day at day 1 and day 8 of each cycle (J1 = J21)~* Prednisone 10 mg/day continuously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel weekly+ Prednisone
Description: * Docetaxel weekly 35 mg/m²/day at day 1 and day 8 of each cycle (J1 = J21)~* Prednisone 10 mg/day continuously
Study: NCT03230747

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Edwards SAPIEN M3 System
Description: SAPIEN M3 System includes the SAPIEN M3 valve and the SAPIEN M3 dock
Study: NCT00551577

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant chemotherapy (Carboplatin/Docetaxel)
Description: 2 cycles of Carboplatin/Docetaxel (3-weekly) preoperative and 4 cycles of Carboplatin/Docetaxel (3-weekly) postoperative
Study: NCT02147054

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex
Description: Effect of Rocuronium will be reversed at the appropriate time using Sugammadex 16mg/kg as a single dose which may be repeated once.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex
Description: Effect of Rocuronium will be reversed at the appropriate time using Sugammadex 16mg/kg as a single dose which may be repeated once.
Study: NCT02407834

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: S1
Description: Immersion in 0.25% sodium hypochlorite for 20 minutes, during 7 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: S2
Description: Immersion in 0.5% sodium hypochlorite for 20 minutes, during 7 days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: S3
Description: Immersion in 10% Ricinus communis for 20 minutes, during 7 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: S4
Description: Immersion in Saline solution for 20 minutes, during 7 days.
Study: NCT03680703

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided Self-Help Behavioral Weight Loss
Description: Participants will be provided with patient-focused materials and worksheets that contain all the necessary information, procedures, and techniques of the behavioral weight loss program. For 12 weeks, treatment will be provided over the internet. This therapy focuses on making gradual and modest lifestyle changes with goals of normalizing eating patterns, decreasing caloric intake, building coping skills, and increasing physical activity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided Self-Help Behavioral Weight Loss
Description: Participants will be provided with patient-focused materials and worksheets that contain all the necessary information, procedures, and techniques of the behavioral weight loss program. For 12 weeks, treatment will be provided over the internet. This therapy focuses on making gradual and modest lifestyle changes with goals of normalizing eating patterns, decreasing caloric intake, building coping skills, and increasing physical activity.
Study: NCT04178031

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IUD insertion
Description: Insert a warm, moistened speculum. Cleanse the cervix with an antiseptic solution. Apply gentle traction with the tenaculum to straighten the canal. Remove the sound by its handle and gently insert to measure the depth of the uterus. Do not apply great force if there is resistance. Apply further traction to the tenaculum and attempt to re-insert the sound at a different angle. Once the sound is inserted and removed, note the depth of the uterine cavity. The woman can expect to feel cramping as the sound is inserted and withdrawn.~Load the IUD and insert it into the uterine cavity according to the manufacturer instructions. As the IUD is inserted through the cervix into the uterus, the patient may have pain and cramping similar to strong menstrual cramps.~Gently remove the tenaculum. Trim the strings of the IUD to 3-4 cm in length Remove the speculum and assess the woman.
Study: NCT01633294

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ampicillin + gentamicin
Description: ampicillin 1 g every six hours and gentamicin 240 mg every day intravenously
Study: NCT00433316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ropivacaine
Description: 1% ropivacaine

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Aeroneb Pro Nezulizer, Aerogen, Ireland
Description: Aeroneb Pro Nezulizer, Aerogen, Ireland
Study: NCT00949455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib ditosylate
Description: Given orally
Study: NCT03878524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of biospecimens (including tissue, blood, or previously collected archival specimens)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Description: Given IV
Study: NCT00949455

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given orally
Study: NCT03356886

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Manipulative Technique
Description: 1) The application of a global low-amplitude and high-speed manipulation at the upper thoracic region between T1 and T5 levels in the dorsal decubitus position and 2) Techniques of post-anterior central mobilization applied for 30 seconds with an average of 30 repetitions in each lumbar vertebra, from L5 to L1, using grade II joint mobilization (patients positioned in the ventral decubitus position).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spinal Manipulative Technique
Description: 1) The application of a global low-amplitude and high-speed manipulation at the upper thoracic region between T1 and T5 levels in the dorsal decubitus position and 2) Techniques of post-anterior central mobilization applied for 30 seconds with an average of 30 repetitions in each lumbar vertebra, from L5 to L1, using grade II joint mobilization (patients positioned in the ventral decubitus position).
Study: NCT02200601

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Seipher Wellness
Study: NCT01580228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dinaciclib
Description: Dinaciclib administered intravenously over 2 hours at a dose of 7 mg/m\^2 on Day 1, 10 mg/m\^2 on Day 8, and 14 mg/m\^2 on Day 15 in Cycle 1. Starting in Cycle 2 and thereafter, dinaciclib will be dosed at 14 mg/m\^2 on Days 1, 8, and 15 of each 28-day cycle for a total of 12 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ofatumumab
Description: Ofatumumab administered intravenously at a dose of 300 mg on Cycle 1 Day 1, followed by 2000 mg on Cycle 1 Days 8, 15, and 22; Cycle 2 Days 1, 8, 15, and 22; followed 5 weeks later on Day 1 of Cycles 4-12.
Study: NCT01101529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant (Emend)
Description: Aprepitant will be added to the standard anti-emetic therapy. Emend is given orally, 125 mg the first day, then 80 mg daily during the chemotherapy course and 7 days after

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered instead of Emend
Study: NCT03377517

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiosurgical hypophysectomy
Description: Patients will be treated to a dose of 150 Gy in a single fraction. All patients will undergo CT simulation with 1 mm slices as well as MRI simulation including at least high resolution 1 mm slice T1 weighted MRI. They will be treated in a supine position using an aquaplast mask system for immobilization.
Study: NCT04271800

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19 CAR-T cells
Description: A single infusion of CD19-CAR-T cells will be administered intravenously.
Study: NCT02471144

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Experimental : Secukinumab low dose
Description: Depending on weight group subject will receive per dose a) 75 mg if weighing less than 50 kg b) 150 mg if weighing 50 kg or more. Secukinumab injections (one or two per dose, depending on the weight group) will be administered subcutaneously at Randomization, Weeks 1, 2, 3, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, and 48, and Placebo secukinumab at Weeks 13, 14 and 15 during the blinded phase of the study; thereafter at Week 52 and every 4 weeks during the extension treatment period until Week 232.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Experimental: Secukinumab high dose
Description: Depending on weight group subject will receive per dose a) 75 mg if weighing less than 25 kg b) 150 mg if weighing between 25 and less than 50 kg c) 300 mg if weighing more than 50 kg. Secukinumab injections (one or two per dose, depending on the weight group) will be administered subcutaneously at Randomization, Weeks 1, 2, 3, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, and 48, and Placebo secukinumab at Weeks 13, 14 and 15 during the blinded phase of the study; thereafter at Week 52 and every 4 weeks during the extension treatment period until Week 232.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: Secukinumab Placebo
Description: Placebo secukinumab (one or two subcutaneous injections per dose, depending on weight group) at Randomization and Weeks 1, 2, 3 4 and 8. At Week 12, subjects in the placebo group based on their PASI 75 response status at Week 12 will proceed as follows: • PASI 75 responders will discontinue study treatment at Week 12 and enter the treatment-free follow-up period • PASI 75 non-responders will receive high dose or low dose secukinumab, according to the pre-assignment at the Randomization visit. They will receive their treatment based on the weight category(\<25 kg, 25- \<50kg, ≥50 kg), on Weeks 12, 13, 14, 15, and then every four weeks starting at Week 16 until Week 48 during the maintenance period; thereafter at week 52 and every 4 weeks during the extension treatment period until Week 232.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Etanercept
Description: Etanercept 0.8 mg/kg of subject weight and up to a maximum of 50 mg per dose. Subcutaneous etanercept 0.8 mg/kg (one or two injections per dose) once per week, for 51 weeks administered at home (self-injected or by caregiver) or at the study site. At Wk 52 subjects in the etanercept group will move into the treatment-free follow up period and terminate the study.
Study: NCT02428829

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Attempt walking from 4 hours post operatively, on the day of their surgery.
Description: Intervention group will be seen by a physiotherapist to attempt walking from 4 hours post operatively, on the day of their surgery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control - standard treatment
Description: standard physiotherapy in line with current hospital protocol including first walking approximately 24 hours post operatively.
Study: NCT03878524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacomitinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darolutamide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Given PO
Study: NCT00769054

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Local Infiltration Analgesia with 1 % Ropivacaine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic NaCl
Description: Local Infiltration with NaCl
Study: NCT02345733

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ulcerative Colitis Diet
Description: we have postulated that a diet that we developed that reduces exposure to dietary ingredients that allow sulfide reducing bacteria to thrive, or that impair the mucous layer, coupled with dietary products that enhance butyrate production, could induce remission in UC without involving additional immune suppression.
Study: NCT03878524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enasidenib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entrectinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Given PO
Study: NCT02345733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotic cocktail
Description: We have postulating that antibiotic therapy can alter the microbiota clinically. Controlling the microbiota by antibiotics may allow for control of the disease without immune suppression
Study: NCT02108886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: 10 mg of Montelukast per day, from admission for preterm labor until delivery or 35 weeks of pregnancy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: empty capsule filled with sugar

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: urine and vaginal secretions sampling
Description: Urine and vaginal secretions sampling, once a week in both groups

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: urine and vaginal secretions sampling
Description: Urine and vaginal secretions sampling, once a week in both groups
Study: NCT03816176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isavuconazonium sulfate
Description: Intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isavuconazonium sulfate
Description: Oral capsule
Study: NCT03994016

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WiseGuyz
Description: The WiseGuyz program was developed by the Centre for Sexuality (Calgary, AB), and aims to reduce male-perpetrated adolescent dating violence, improve mental and sexual health, and support youth to build healthier, more inclusive relationships in their peer groups, schools and communities, by helping participants identify and deconstruct gender role norms.~WiseGuyz is offered during instructional time by community-based facilitators from the Centre for Sexuality. WiseGuyz is comprised of 20 sessions across four modules. These sessions typically take the full school year (September-May) to implement.
Study: NCT03878524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idelalisib
Description: Given PO
Study: NCT04051606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Regorafenib is a monotherapy during the study, oral administration at 160 mg once daily will be administered for 3 weeks on /1 week off.
Study: NCT01355757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single Injection of Local Anesthetic
Description: Single injection of 20 ml ropivacaine 0.5%
Study: NCT04161534

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KT Tape
Description: in addition to an arm sling, KT Tape will be applied to stabilize the clavicle fracture, thereby decreasing motion and pain.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Arm Sling
Description: An arm sling will be applied to stabilize the clavicle fracture, thereby decreasing motion and pain.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arm Sling
Description: An arm sling will be applied to stabilize the clavicle fracture, thereby decreasing motion and pain.
Study: NCT04319757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACE1702
Description: ACE1702 cellular therapy (anti-HER2 oNK cells) given intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACE1702
Description: ACE1702 cellular therapy (anti-HER2 oNK cells) given intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACE1702
Description: ACE1702 cellular therapy (anti-HER2 oNK cells) given intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACE1702
Description: ACE1702 cellular therapy (anti-HER2 oNK cells) given intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACE1702
Description: ACE1702 cellular therapy (anti-HER2 oNK cells) given intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACE1702
Description: ACE1702 cellular therapy (anti-HER2 oNK cells) given intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lympho-conditioning agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lympho-conditioning agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lympho-conditioning agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lympho-conditioning agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lympho-conditioning agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lympho-conditioning agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lympho-conditioning agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lympho-conditioning agent
Study: NCT03356886

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pain Neuroscience Education
Description: All participants in the PNE + SMT group will initially receive a workshop on PNE in which different concepts of pain neuroscience and pain reconceptualization will be discussed and a power-point presentation with metaphors and animated videos on the topic will be employed. The PNE program will be held in 2 sessions of 40 minutes each. The topics of the intervention program will be divided into four thematic topics according to Explain Pain concepts.
Study: NCT00052026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carvedilol
Description: low-dose carvedilol administered twice daily for 8 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: administered twice daily for 8 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carvedilol
Description: high-dose carvedilol administered twice daily for 8 months
Study: NCT04319757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lympho-conditioning agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lympho-conditioning agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lympho-conditioning agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lympho-conditioning agent
Study: NCT03875638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: Levetiracetam is an antiepileptic medication that has been shown to reduced network cortical hyperexcitability

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: Levetiracetam is an antiepileptic medication that has been shown to reduced network cortical hyperexcitability

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: The placebo is a capsule that is identical in appearance to the levetiracetam